MSME (Udyam registered) Ministry of MSME
- Category
- Medium (2022-23)
- Udyam number
- UDYAM-TS-02-0000075
Market Cap
₹137 Cr
GODAVARI · BSE
Share Price
₹127.00
+1.11% today
Revenue
₹106 Cr
FY 2025-26 · -6.7% YoY
EBITDA
₹10.30 Cr
Margin 9.7%
Net Profit
₹3.65 Cr
FY 2025-26 · -15.7% YoY
P/E (TTM)
35.3x
P/B 1.8x
ROE
6.9%
ROCE 6.8%
Debt / Equity
1.23
Interest cover 50.6x
About Godavari Drugs Limited
Data last updated:
Godavari Drugs Limited is a public limited company based in Secunderabad, Telangana, India. It operates in the specialty chemicals segment of the chemicals and materials sector. It was incorporated on 02 December 1987 and has been in existence for over 39 years.
The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24230TG1987PLC008016. Its GSTIN is 27AAACG8039Q1Z0 (Maharashtra). The company holds 3 GST registrations, of which 1 is active. It is a listed company as per MCA records. Its shares are listed on BSE: 530317.
The company has an authorised share capital of ₹20 Cr and a paid-up capital of ₹10.13 Cr. It was formerly known as Godavari Drugs Private Limited. It is led by directors including Mukund Kakani (Managing Director) and Mohit Jaju (Whole-Time Director).
Its last annual general meeting (AGM) was held on 27 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 1 – 8 – 303/34 S.P. Road Secunderabad. Secunderabad, Telangana, India – 500003.
As per the latest standalone financials for FY 2025-26, the company reported a revenue of ₹105.81 Cr, a decline of 6.7% compared to the previous year. For the same year it recorded a net profit of ₹3.65 Cr (net margin 3.4%) and EBITDA of ₹10.3 Cr (EBITDA margin 9.7%). The net worth stands at ₹75.8 Cr (up 74.9% YoY). Total assets are valued at ₹158.45 Cr (up 46% YoY).
The company has about 92 employees on its provident fund (EPFO) records.
The company is associated with 1 brand: Godavaridrugs. As per MCA filings, the company has open charges of ₹91.64 Cr and satisfied charges of ₹110.23 Cr on record. Court records list 46 cases involving the company, including 17 filed by the company and 29 filed against it; 7 cases are pending. The company has 35 deals on record (35 market trades); the latest was in January 2026. Its 10 peer companies in the Chemicals industry (API Manufacturers, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 5 larger and 5 smaller; the largest is Element Chemilink Private Limited with revenue of ₹115.09 Cr.
Godavari Drugs Limited is registered as a medium enterprise under the Udyam registration framework (Reg. No. UDYAM-TS-02-0000075). The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website godavaridrugs.com.
Company details
CIN L24230TG1987PLC008016
Registration Number 008016
Incorporation Date 02 December 1987
ROC Hyderabad
Listing Status Listed - Listed on BSE (530317)
Company Status Active
Date of Last AGM 27 September 2025
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant
MSME Classification Medium
Udyam Registration UDYAM-TS-02-0000075
CIN history
Godavari Drugs has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24230TG1987PLC008016, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L24230TG1987PLC008016 | Current |
| L24230AP1987PTC008016 | Previous |
| L24230AP1987PLC008016 | Previous |
Recognitions & Rankings of Godavari Drugs
Contact details
Godavari Drugs Limited's registered office is in Secunderabad, Telangana. Its website is godavaridrugs.com. Its e-mail address and telephone number are in the company report.
- Email
- Telephone
- Website
- Registered Address1 – 8 – 303/34 S.P. Road Secunderabad. Secunderabad, Telangana, India – 500003
- IndustryChemicals and Materials, Specialty Chemicals
To see the full contact details of Godavari Drugs Limited, buy the company report.
Comprehensive company report
Godavari Drugs Limited - one report that includes everything
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included
Brands
Godavari Drugs operates one associated brand: Godavaridrugs. Each brand links to its own profile.
| Brand | Description | Website |
|---|---|---|
| CMO services for APIs, intermediates, and fine chemicals are offered. | godavaridrugs.com |
Business activity
The main business activity of Godavari Drugs is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C6 | Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products |
To see the full business activity and turnover split of Godavari Drugs Limited, buy the company report.
Financials of Godavari Drugs Limited
FY 2025-26 filings availableGodavari Drugs Limited reported revenue of ₹105.81 Cr (down 6.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · StandaloneRevenue
₹106 Cr
-6.7% YoY
EBITDA
₹10.30 Cr
-12.9% YoY
Profit After Tax
₹3.65 Cr
-15.7% YoY
Net Worth
₹75.80 Cr
+74.9% YoY
Total Assets
₹158 Cr
+46.0% YoY
Total Debt
₹81.94 Cr
+27.3% YoY
Revenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 106 | 113 | 157 | 160 | 161 | 123 | 95.70 |
| Revenue growth | -6.7% | -27.7% | -1.8% | -0.9% | +31.3% | +28.2% | - |
| EBITDA | 10.30 | 11.82 | 13.22 | 9.92 | 11.30 | 9.83 | 6.03 |
| EBITDA margin | +9.7% | +10.4% | +8.4% | +6.2% | +7.0% | +8.0% | +6.3% |
| Profit before tax | 5.05 | 5.62 | 6.93 | 4.93 | 7.03 | 5.70 | 2.29 |
| Net profit | 3.65 | 4.33 | 5.62 | 3.60 | 5.25 | 4.12 | 2.00 |
| Net profit margin | +3.5% | +3.8% | +3.6% | +2.3% | +3.3% | +3.4% | +2.1% |
| EPS (₹) | 4.04 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | 2.66 |
| Balance sheet | |||||||
| Total assets | 158 | 109 | 97.49 | 69.98 | 53.43 | 55.63 | 48.53 |
| Net worth | 75.80 | 43.35 | 38.97 | 33.42 | 29.63 | 24.39 | 20.26 |
| Total debt | 81.94 | 64.35 | 57.77 | 35.85 | 23.07 | 30.46 | 27.60 |
| Cash & bank | 14.51 | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 |
| Net working capital | 71.61 | 46.11 | 53.06 | 37.19 | 27.86 | 33.07 | 26.01 |
| Cash flow | |||||||
| Cash from operations | 0.73 | 11.20 | 18.41 | 13.22 | 11.23 | 1.33 | 6.24 |
| Cash from investing | (25.95) | (19.51) | (13.22) | (8.64) | (4.97) | (1.25) | (6.68) |
| Cash from financing | 37.35 | 8.07 | (5.65) | (3.77) | (5.62) | 0.13 | 0.34 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27.96 | 33.16 | 22.18 | 26.65 | 23.81 | 25.50 | 29.55 | 26.09 |
| Revenue growth (YoY) | +17.4% | +30.0% | -24.9% | +2.2% | -26.1% | - | - | - |
| Other income | 0.15 | 0.25 | 0.27 | 0.64 | 0.01 | 0.11 | 0.10 | 0.01 |
| Total expenses | 25.44 | 30.22 | 19.71 | 24.65 | 20.91 | 22.39 | 26.97 | 23.18 |
| EBITDA | 2.52 | 2.94 | 2.47 | 2.00 | 2.90 | 3.11 | 2.58 | 2.91 |
| EBITDA margin | +9.0% | +8.9% | +11.1% | +7.5% | +12.2% | +12.2% | +8.7% | +11.2% |
| Depreciation | 0.59 | 0.61 | 0.61 | 0.60 | 0.60 | 0.67 | 0.64 | 0.58 |
| Interest | 0.90 | 0.96 | 1.11 | 0.91 | 1.00 | 1.11 | 1.11 | 1.08 |
| Profit before tax | 1.18 | 1.62 | 1.02 | 1.13 | 1.31 | 1.44 | 0.93 | 1.26 |
| Tax | 0.07 | 0.33 | 0.26 | 0.12 | 0.26 | 0.55 | 0.15 | 0.16 |
Financial Statements
Figures in ₹ Cr; negatives in brackets. Updated 02 Nov 2026
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 27.96 | 33.16 | 22.18 | 26.65 | 23.81 | 25.50 | 29.55 | 26.09 |
| Revenue growth (YoY) | +17.4% | +30.0% | -24.9% | +2.2% | -26.1% | - | - | - |
| Other income | 0.15 | 0.25 | 0.27 | 0.64 | 0.01 | 0.11 | 0.10 | 0.01 |
| Total expenses | 25.44 | 30.22 | 19.71 | 24.65 | 20.91 | 22.39 | 26.97 | 23.18 |
| EBITDA | 2.52 | 2.94 | 2.47 | 2.00 | 2.90 | 3.11 | 2.58 | 2.91 |
| EBITDA margin | +9.0% | +8.9% | +11.1% | +7.5% | +12.2% | +12.2% | +8.7% | +11.2% |
| Depreciation | 0.59 | 0.61 | 0.61 | 0.60 | 0.60 | 0.67 | 0.64 | 0.58 |
| Interest | 0.90 | 0.96 | 1.11 | 0.91 | 1.00 | 1.11 | 1.11 | 1.08 |
| Profit before tax | 1.18 | 1.62 | 1.02 | 1.13 | 1.31 | 1.44 | 0.93 | 1.26 |
| Tax | 0.07 | 0.33 | 0.26 | 0.12 | 0.26 | 0.55 | 0.15 | 0.16 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 106 | 113 | 157 | 160 | 161 | 123 | 95.70 |
| Revenue growth | -6.7% | -27.7% | -1.8% | -0.9% | +31.3% | +28.2% | - |
| Other income | 1.16 | 0.98 | 0.62 | 0.88 | 0.28 | 0.41 | 0.33 |
| Total expenses | 95.51 | 102 | 143 | 150 | 150 | 113 | 89.67 |
| Employee cost | 5.70 | 5.03 | 5.13 | 4.84 | 4.96 | 3.94 | 3.45 |
| EBITDA | 10.30 | 11.82 | 13.22 | 9.92 | 11.30 | 9.83 | 6.03 |
| EBITDA margin | +9.7% | +10.4% | +8.4% | +6.2% | +7.0% | +8.0% | +6.3% |
| Depreciation | 2.43 | 2.45 | 1.99 | 1.94 | 1.70 | 1.22 | 1.16 |
| Interest | 3.98 | 4.73 | 4.92 | 3.93 | 2.85 | 3.32 | 2.91 |
| Profit before tax | 5.05 | 5.62 | 6.93 | 4.93 | 7.03 | 5.70 | 2.29 |
| Tax | 0.97 | 1.25 | 1.38 | 1.15 | 1.78 | 1.58 | 0.29 |
| Net profit | 3.65 | 4.33 | 5.62 | 3.60 | 5.25 | 4.12 | 2.00 |
| Net profit margin | +3.5% | +3.8% | +3.6% | +2.3% | +3.3% | +3.4% | +2.1% |
| EPS (₹) | 4.04 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | 2.66 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | 10.13 | 7.53 | 7.53 | 7.53 | 7.53 | 7.53 | 7.53 |
| Reserves & surplus | 60.42 | 35.82 | 31.44 | 25.89 | 22.10 | 16.86 | 12.73 |
| Shareholders' funds (net worth) | 75.80 | 43.35 | 38.97 | 33.42 | 29.63 | 24.39 | 20.26 |
| Secured loans | 60.36 | 49.86 | 47.77 | 10.61 | 5.10 | 7.23 | 19.57 |
| Unsecured loans | 21.58 | 14.49 | 10.00 | 25.24 | 17.97 | 23.23 | 8.03 |
| Total debt | 81.94 | 64.35 | 57.77 | 35.85 | 23.07 | 30.46 | 27.60 |
| Total liabilities | 158 | 109 | 97.49 | 69.98 | 53.43 | 55.63 | 48.53 |
| Assets | |||||||
| Gross block | 49.49 | 49.43 | 46.88 | 46.28 | 49.57 | 44.05 | 34.21 |
| Net block | 30.31 | 32.61 | 26.69 | 24.91 | 26.25 | 22.43 | 13.81 |
| Capital work in progress | 56.54 | 29.95 | 18.32 | 9.08 | 0.49 | 0.76 | 8.93 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 46.06 | 27.94 | 20.65 | 19.86 | 10.03 | 14.65 | 17.75 |
| Sundry debtors | 43.58 | 42.32 | 59.42 | 57.93 | 55.58 | 45.12 | 36.02 |
| Cash & bank balances | 14.51 | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 |
| Loans & advances | 7.64 | 6.12 | 5.78 | 6.13 | 6.45 | 6.20 | 5.63 |
| Total current assets | 112 | 78.75 | 88.47 | 87.00 | 74.34 | 67.61 | 60.83 |
| Total current liabilities | 40.18 | 32.64 | 35.41 | 49.81 | 46.48 | 34.54 | 34.82 |
| Net working capital | 71.61 | 46.11 | 53.06 | 37.19 | 27.86 | 33.07 | 26.01 |
| Total assets | 158 | 109 | 97.49 | 69.98 | 53.43 | 55.63 | 48.53 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 | 1.53 |
| Net cash from operating activities | 0.73 | 11.20 | 18.41 | 13.22 | 11.23 | 1.33 | 6.24 |
| Net cash from investing activities | (25.95) | (19.51) | (13.22) | (8.64) | (4.97) | (1.25) | (6.68) |
| Net cash from financing activities | 37.35 | 8.07 | (5.65) | (3.77) | (5.62) | 0.13 | 0.34 |
| Net change in cash | 12.14 | (0.25) | (0.46) | 0.81 | 0.64 | 0.21 | (0.10) |
| Closing cash | 14.51 | 2.37 | 2.62 | 3.08 | 2.28 | 1.64 | 1.43 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| Sales growth | -6.7% | -27.7% | -1.8% | -0.9% | +31.3% | +28.2% | - |
| EBITDA growth | -12.9% | -10.6% | +33.3% | -12.2% | +15.0% | +63.0% | - |
| PBT growth | -10.1% | -18.9% | +40.6% | -29.9% | +23.3% | +148.9% | +31.6% |
| Net income growth | -15.7% | -23.0% | +56.1% | -31.4% | +27.4% | +106.0% | - |
| Revenue CAGR (3Y) | -12.8% | -11.1% | +8.5% | +18.6% | +24.5% | +23.9% | +8.2% |
| EBITDA CAGR (3Y) | +1.3% | +1.5% | +10.4% | +18.1% | +27.3% | +34.5% | +4.9% |
| Profitability & leverage | |||||||
| Net income margin | +3.9% | +3.9% | +3.5% | +2.4% | +3.3% | +3.4% | +2.1% |
| Return on capital employed | +6.8% | +10.1% | +14.1% | +14.4% | +18.1% | +17.3% | +11.6% |
| Return on net worth | +6.9% | +10.6% | +15.3% | +12.0% | +19.4% | +18.5% | +10.2% |
| Debt / equity | 1.23 | 1.48 | 1.29 | 0.93 | 0.99 | 1.30 | 1.29 |
| Long-term debt / equity | 0.49 | 0.38 | 0.29 | 0.38 | 0.49 | 0.57 | 0.50 |
| Interest cover | 50.57 | 50.48 | 43.81 | 49.25 | 29.69 | 38.56 | 59.75 |
| Efficiency & per share | |||||||
| Fixed asset turnover | 2.14 | 2.35 | 3.36 | 3.33 | 3.44 | 3.13 | 2.80 |
| Inventory turnover | 2.86 | 4.67 | 7.74 | 10.68 | 13.06 | 7.57 | 5.59 |
| Debtors turnover | 2.46 | 2.23 | 2.67 | 2.81 | 3.20 | 3.02 | 2.74 |
| EPS (₹) | 4.04 | 5.82 | 7.37 | 5.03 | 6.97 | 5.48 | 2.66 |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 69.66 | 57.56 | 51.74 | 44.38 | 39.35 | 32.38 | 26.90 |
To see the full year-wise statements and ratios of Godavari Drugs Limited, buy the company report.
Board of directors of Godavari Drugs Limited
Godavari Drugs has 6 current directors and 9 former directors. Current directors are listed first, with their designation and appointment date.
Current Directors
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Mohit Jaju | Whole-Time Director | 10 May 2012 | 14 Years 5 Months | Current |
| Mukund Kakani Also directs: Godavari Capital Private Limited | Managing Director | 03 Dec 1987 | 38 Years 10 Months | Current |
| Ghanshyam Jaju | Director | 03 Dec 1987 | 38 Years 10 Months | Current |
| Mahendra Uday Bhalerao Also directs: Nichino India Private Limited | Director | 12 Nov 2022 | 3 Years 11 Months | Current |
| Shilpa Bung Also directs: Naughty Rabbit LLP, Sigachi Laboratories Limited, Adon Agro Commodities Limited and 2 more | Director | 29 May 2025 | 1 Years 5 Months | Current |
| Dinesh Udpa Also directs: Neuton Auto Private Limited | Director | 13 Feb 2024 | 2 Years 8 Months | Current |
Peer comparison
Godavari Drugs Limited is compared with the 10 companies closest to it by revenue in the Chemicals industry (API Manufacturers, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Element Chemilink Private Limited | ₹115.09 Cr (FY 2025) | 31.0% | Gujarat, India | |||
| Cera-Chem Private Limited | ₹115.05 Cr (FY 2025) | 9.0% | Chennai, Tamil Nadu, India | |||
| LRC Speciality Chemicals Private Limited | ₹115.04 Cr (FY 2024) | -35.0% | Mumbai, Maharashtra, India | |||
| Fairmate Chemicals Private Limited | ₹114.67 Cr (FY 2024) | 32.0% | Ahmedabad, Gujarat, India | |||
| Rishabh Metals & Chemicals Private Limited | ₹114.66 Cr (FY 2025) | 9.0% | Mumbai, Maharashtra, India | |||
| Archimedis Laboratories Private Limited | ₹114.19 Cr (FY 2025) | 22.0% | Hyderabad, Telangana, India | |||
| Orient Micro Abrasives Limited | ₹113.98 Cr (FY 2024) | -1.0% | Delhi, India | |||
| VDH Chem Tech Private Limited | ₹113.57 Cr (FY 2025) | -28.0% | Delhi, India | |||
| Glochem Industries Private Limited | ₹113.55 Cr (FY 2025) | -7.0% | Hyderabad, Telangana, India | |||
| Venkar Chemicals Private Limited | ₹112.58 Cr (FY 2024) | 61.0% | Hyderabad, Telangana, India | |||
| Godavari Drugs Limitedthis company | ₹105.81 Cr (FY 2026) | ₹3.65 Cr | 3.4% | -6.7% | 92 | Secunderabad, Telangana, India |
To see the full peer comparison of Godavari Drugs Limited, buy the company report.
Auditor
Godavari Drugs Limited is audited by Ayyadevara & Co for the financial year 2023.
| Auditor firm | Financial year | Firm registration number |
|---|---|---|
| Ayyadevara & Co | FY 2023 | 00278S |
Shareholding
Shareholding for the quarter ended Mar 2026: promoters hold 40.20%, foreign institutional investors hold 0.00%, domestic institutional investors hold 2.50% and retail and other public shareholders hold 57.30%.
Mar 2026
QUARTER
40.20% Promoters
2.50% DII (Domestic Institutional)
57.30% Retail & Others
Promoter holding - history
Now 40.20% · Mar 2026High 52.60% · Jun 2025Low 40.20% · Mar 2026
Shareholding trend - last 6 quarters
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | |
|---|---|---|---|---|
| Promoters | 40.20% | 52.60% | 52.60% | 52.60% |
| Public | 59.80% | 47.40% | 47.40% | 47.40% |
Charges & borrowings
Open charges
₹91.64 Cr
Satisfied charges
₹110.23 Cr
Breakdown by lending institutions
Latest charge details
| Date | Charge ID | Lender | Amount | Status | Modified or satisfied on |
|---|---|---|---|---|---|
| 18 Feb 2025 | 101048560 | Others | ₹43.4 Cr | Open | |
| 05 Jul 2018 | 100199796 | Yes Bank Limited | ₹48.24 Cr | Open | |
| 31 May 2022 | 100579862 | The Hongkong and Shanghai Banking Corporation Limited | ₹2.9 Cr | Satisfied | |
| 30 Mar 2022 | 100563735 | The Hongkong and Shanghai Banking Corporation Limited | ₹43.4 Cr | Satisfied | |
| 10 Apr 2017 | 100095670 | Others | ₹3.7 Cr | Satisfied |
To see the full charge records of Godavari Drugs Limited, buy the company report.
Total charge records: 23 View all charges
Deals & funding
Godavari Drugs Limited has 35 deals on record (35 market trades); the latest was in January 2026.
Total deals
35
Market trades
35
Deals on record (5 of 35)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Jan 2026 | Market trade | ₹38.8 Lakh | Buyer: Tradelink Exim (India) Private Limited |
| Dec 2022 | Market trade | ₹1.3 Cr | Buyer: Yuga Stocks & Commodities Private Limited , Arham Share Private Limited Seller: Yuga Stocks & Commodities Private Limited , Arham Share Private Limited , an individual |
| Jan 2021 | Market trade | ₹21.2 Lakh | Seller: P.C.S.Securities Limited |
| Mar 2020 | Market trade | ₹33.6 Lakh | Buyer: 3 individuals Seller: Autofin Ltd |
| Feb 2015 | Market trade | ₹49.8 Lakh | Buyer: BP Comtrade Private Limited Seller: BP Comtrade Private Limited |
To see the full deal history of Godavari Drugs Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
Godavari Drugs Limited has 46 court cases on record: 17 filed by Godavari Drugs, 29 filed against it. 7 cases are pending and 39 are disposed.
Total cases
46
Filed by the company
17
Filed against the company
29
Pending
7
Disposed
39
Cases by court
| Court | Cases | Against the company | Pending |
|---|---|---|---|
| District courts | 28 | 16 | 6 |
| High courts | 16 | 12 | 1 |
| Supreme Court | 1 | 1 | 0 |
| NCLT | 1 | 0 | 0 |
Cases on record (5 of 46)
| Court | Type of case | Party | Status |
|---|---|---|---|
| District court, Hyderabad CCC, Telangana | Cheque dishonour complaint | Filed by the company against M/S. Affine Formulations Ltd Rep by Pradhyaman Nyati | Pending |
| High Court, TELANGANA | Court case (CCCA) | Filed by the company against M/S. Basundhara Realtors Pvt. Ltd and 10 others | Pending |
| District court, Hyderabad CCC, Telangana | Court case (T.R.CRLMP) | Filed by the company against M/S. Somil Enterprises Pvt.Ltd., Rep.By Sanjay Manharlal Shah | Disposed |
| High Court, TELANGANA | Court case (CRLP) | Filed by the company against M/S. Somil Enterprises Pvt. Ltd. and 2 others | Disposed |
| NCLT, Jaipur | Insolvency matter | Filed by the company against Rajasthan Drugs and Pharmaceuticals Ltd | Disposed |
To see the full case history of Godavari Drugs Limited, buy the company report.
Case records are compiled from court listings and may lag the court's own records. A case filed against a company is not a finding against it.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Godavari Drugs Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
Employees & EPFO
Godavari Drugs Limited has a workforce of 92 employees on its EPFO records as of Apr 07, 2024, across 1 active EPFO establishment.
Employee count
92
Active EPFO establishments
1
Employee growth
2.22%
GST
Godavari Drugs has 3 GST registrations: 1 active and 2 cancelled or inactive.
Total GSTINs
3
Active
1
Cancelled / inactive
2
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAACG8039Q1Z0 | Maharashtra | Active | 01 Jul 2017 |
To see the full GST registrations and return filing status of Godavari Drugs Limited, buy the company report.
Recent activity
Godavari Drugs Limited has 19 board changes on record since 1987: 13 appointments and 6 cessations. The latest: Syed Anis Hussain ceased to be Director on 23 Jun 2025.
Filing
Godavari Drugs Limited has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
AGM
Godavari Drugs Limited last Annual general meeting of members was held on 27 Sep 2025 as per latest MCA records.
Ceased
Syed Anis Hussain ceased to be Director.
Ceased
Vimala Behram Madon ceased to be Director.
Appointed
Shilpa Bung was appointed as Director.
Charges
A charge with Others of Rs. 43.40 Cr registered on 18 Feb 2025 with Charge ID 101048560 was modified on 22 May 2025.
Charges
A charge registered on 31 May 2022 via Charge ID 100579862 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 15 Apr 2025.
Charges
A charge registered on 30 Mar 2022 via Charge ID 100563735 with The Hongkong And Shanghai Banking Corporation Limited was fully satisfied on 15 Apr 2025.
Charges
A charge with Others amounted to Rs. 43.40 Cr with Charge ID 101048560 was registered on 18 Feb 2025.
Charges
A charge with Yes Bank Limited of Rs. 48.24 Cr registered on 05 Jul 2018 with Charge ID 100199796 was modified on 29 Jun 2024.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 2.90 Cr registered on 31 May 2022 with Charge ID 100579862 was modified on 11 Jun 2024.
Charges
A charge with The Hongkong And Shanghai Banking Corporation Limited of Rs. 43.40 Cr registered on 30 Mar 2022 with Charge ID 100563735 was modified on 11 Jun 2024.
67 earlier events are in the company report.
Frequently asked questions
Godavari Drugs is an active public limited company based in Secunderabad, Telangana, India. The company works in specialty chemicals, within the chemicals and materials industry. It was incorporated on 02 December 1987 (39+ years old) and is registered under CIN L24230TG1987PLC008016. Listed on BSE: 530317.
Godavari Drugs reported revenue of ₹105.81 Cr for FY 2025-26 (down 6.7% YoY) based on standalone financials.
Godavari Drugs has 6 current directors:
- Mukund Kakani - Managing Director
- Mohit Jaju - Whole-Time Director
- Ghanshyam Jaju - Director
- Mahendra Uday Bhalerao - Director
- Shilpa Bung - Director
- Dinesh Udpa - Director
The latest financial statements of Godavari Drugs on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 27 September 2025. Year-wise statements from 2015 are in the company report.
The GSTIN of Godavari Drugs is 27AAACG8039Q1Z0, registered in Maharashtra. The company has 3 GST registrations in all, of which 1 is active and 2 are cancelled or inactive.
The CIN (Corporate Identification Number) of Godavari Drugs is L24230TG1987PLC008016. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Godavari Drugs is a listed company as per MCA records. Its shares are listed on BSE (code: 530317).
Godavari Drugs has 46 court cases on record: 17 filed by the company and 29 filed against it. 7 are pending. Most are in the district courts.
Godavari Drugs was incorporated on 02 December 1987, making it 39+ years old. It is registered with the Registrar of Companies, Hyderabad.
Godavari Drugs has 35 deals on record (35 market trades); the latest was in January 2026.
The peers of Godavari Drugs by revenue are Element Chemilink Private Limited, Cera-Chem Private Limited, LRC Speciality Chemicals Private Limited, Fairmate Chemicals Private Limited, Rishabh Metals & Chemicals Private Limited and 5 more, all in the Chemicals industry (API Manufacturers, Specialty Chemicals), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).
Sample company reports
The same report you get when you buy one: financials, directors, ownership, deals, charges, legal cases, brands and filings, with the Excel workbook alongside.
Swiggy Limited Listed company · 92 pages
BharatPe (Resilient Innovations Pvt Ltd) Unlisted company · 78 pages